INTRODUCTION AND OBJECTIVES: Cancer stem cells
, that closely correlated with tumor growth, metastasis and provide a plausible explanation for chemoresistance and cancer relapse. CSCs were isolated and enriched from carcinoma cells usually, which were inconvenient, low-efficient, and even unreliable. The purpose of this study was to establish prostate CSCs converted from mouse induced pluripotent stem (iPS) cells, that would allow us to monitoring tumor progression and tracking novel drug response.
METHODS: We converted mouse iPS cells into prostate CSCs with defined carcinoma microenvironment following exposure to conditioned medium (CM) derived from RM9-KLK3, a mouse prostate cancer cell line encoded by human KLK3/PSA gene. We also evaluated the expression of various stemness genes and cancer stem cell surface markers, including Oct3/4, Sox2, Nanog, Klf-4, c-Myc, CD44 and CD133, accompanied with the prostate special antigen (PSA) in these cells. In addition, in vivo transplantation experiment was performed to confirmed the tumorigenicity. Furthermore, we used these model on assess new drug response.
RESULTS: These induction CSCs expressed embryonic stem cell markers, accompanied by significantly elevated expression of CSCs surface markers and PSA. Moreover, after subcutaneous injection into C57BL/6 mice, these cells displayed high tumorigenicity. The tumor derived from CSCs exhibited malignant phenotype and showed high expression of Ki-67 and CD31. We also confirmed that novel drug, such as cancer stemness inhibitor suppressed these induction cells significantly compared to the chemotherapy (in vitro and in vivo assay). RT-PCR and Western blot analysis suggested the possible mechanism underlying this effect was dependent on suppressing cancer stemness.
CONCLUSIONS: An efficient approach to enrich CSCs is extremely important for advancing cancer research. In current study, we converted mouse iPS cells into prostate CSCs with defined carcinoma niche. It is noteworthy that these induction CSCs model displayed stemness accompanied by high tumorigenicity, which could help design better agent for cancer therapeutic and suppress cancer relapse.
Source of Funding: An efficient approach to enrich CSCs is extremely important for advancing cancer research. In current study, we converted mouse iPS cells into prostate CSCs with defined carcinoma niche. It is noteworthy that these induction CSCs model displayed stemness accompanied by high tumorigenicity, which could help design better agent for cancer therapeutic and suppress cancer relapse.
MP41-13 AMNIOTIC FLUID FOR THE TREATMENT OF ERECTILE DYSFUNCTION
Michael Zahalsky*, Gina Dessources, Melissa Marchand, Coral Springs, FL; Jason Levy, Philadephia, PA INTRODUCTION AND OBJECTIVES: There is demand for a non-pharmaceutical approach to treating Erectile Dysfunction (ED). Proflo is Amniotic Fluid (AF) which contains various cytokines and growth factors and is believed to facilitate angiogenesis and decrease inflammation. Therefore, it may prove to be a non-pharmacologic, longterm, cost effective alternative to treat ED. To determining the effectiveness of AF as a sustainable treatment for ED METHODS: A retrospective chart review of patients injected with ProFlo AF was performed. Proflo is amniotic fluid from a FDA cleared tissue bank, Vivex. It meets all the criteria to be regulated under the Public Health Service Act section 361. It is minimally manipulated, not combined with anything, not dependent on the metabolic activity of living cells, and being used homologously, since it is from the Genitourinary System and being used on the Genitourinary system. According to FDA draft guidance, Amniotic Fluid is a nonstructural biologic product that serves a biochemical role. A Penile Doppler measuring peak systolic velocity (PSV) and the International Index of Erectile Function Questionnaire (IIEF-5) were used to assess changes in erectile function. Patients were injected with 1cc -2cc's of AF, and followed up to 6 months.
RESULTS: 35 patients were injected with ProFlo AF. 15 patients injected with AF had pre and post PSV values, 12 patients had pre and post IIEF-5 scores. The average PSV after Trimix injection before administering AF was 26.65 cm/s. After AF injection in follow up, the average PSV was 37.83 cm/s (two-tailed t-test p-value < 0.005). Similarly, an increase was observed in the IIEF score for the group. IIEF score ranged from 5 to 21.5 before the initial AF injection and were between 8 to 24 after AF injection (two-tailed t-test p-value < 0.05). Patients only complaints were of minimal bruising and pain at the injection site for 2-7 days after injections.
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THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 CONCLUSIONS: Our results are very promising and statistically significant. We found improved erections on ultrasound and by patient reporting. The majority of patients expressed satisfaction with overall results following injections. Previously, safety data from multiple institutions has been reported on ProFlo Amniotic Fluid. This is the first study to evaluate the effectiveness of ProFlo AF injections. ProFlo AF needs larger studies but may prove to be a safe, effective and noninvasive treatment in men with ED.
Source of Funding: None

MP41-14 HUMAN URINE-DERIVED STEM CELLS GENETICALLY-MODIFIED WITH PEDF IMPROVE CAVERNOUS NERVE INJURY-INDUCED ERECTILE DYSFUNCTION IN A RAT MODEL
Qiyun Yang*, Xin Chen, Tao Zheng, Kai Xia, Xiangzou Sun, Guihua Liu, Guangzhou, China, People's Republic of; Yuanyuan Zhang, WinstonSalem, NC; Chunhua Deng, Guangzhou, China, People's Republic of INTRODUCTION AND OBJECTIVES: The aim of this study was to investigate whether intracavernous injection of urine-derived stem cells (USCs) or USCs overexpressing pigment epithelium-derived factor (PEDF) could protect the erectile function and cavernous structure in a bilateral cavernous nerve injury-induced erectile dysfunction (CNIED) rat model. METHODS: USCs were cultured from the urine of eight healthy male donors. Seventy-five rats were randomly divided into five groups (n ¼ 15 per group): sham, bilateral cavernous nerve (CN) crush injury (BCNI), USC, GFP-USC , and PEDF-USC groups. The sham group received only laparotomy without CN crush injury and intracavernous injection with phosphate-buffered saline (PBS). All of the other groups were subjected to BCNI and intracav-ernous injection with PBS, USCs, GFP-USCs, or GFP/PEDF-USCs, respectively. The total intracavernous pressure (ICP) and the ratio of ICP to mean arterial pressure (ICP/MAP) were recorded. The penile dorsal nerves, the endothelium, and the smooth muscle were assessed within the penile tissue.
RESULTS: The penile dorsal nerves, the endothelium, and the smooth muscle were assessed within the penile tissue. The USC and PEDF-USC groups displayed more significantly enhanced ICP and ICP/MAP ratio (p < 0.05) 28 days after cell transplantation. Immunohistochemistry (IHC) and Western blot analysis demonstrated that the protection of erectile function and the cavernous structure by PEDF-USC was associated with an increased number of nNOS-positive fibers within the penile dorsal nerves, improved expression of endothelial markers (CD31 and eNOS) and smoothelin, an enhanced smooth muscle to collagen ratio, decreased expression of TGF-b1, and decreased cell apoptosis in the cavernous tissue.
CONCLUSIONS: The paracrine effect of USCs and PEDFUSCs prevented the destruction of erectile function and the cavernous structure in the CNIED rat model by nerve protection, thereby improving endothelial cell function, increasing the smooth muscle content, and decreasing fibrosis and cell apoptosis in the cavernous tissue.
Source of Funding: the National Natural Science Foundation of China (Nos. 81471449, and 81401197)
MP41-15 STEM CELL ACTIVATION IN THE MAJOR PELVIC GANGLION IS ENHANCED BY STROMAL DERIVED FACTOR-1 PENILE INJECTIONS FOLLOWING NERVE INJURY
Nikolai Sopko*, Baltimore, MD; Hotaka Matsui, Tokyo, Japan; Takahiro Yoshida, Xiaopu Liu, Max Kates, Trinity Bivalacqua, Baltimore, MD INTRODUCTION AND OBJECTIVES: Stem cells are believed to play a role in nerve regeneration following nerve injury. Stromal Derived Factor-1 (SDF1) is potent stem cell chemokine. We investigated whether penile injections with SDF1 following bilateral nerve crush injury (BCNI) can enhance stem cell recruitment and activation in the major pelvic ganglion (MPG).
METHODS: Sprague Dawley (350g) male rats underwent sham procedure or BCNI (n¼10/group). Starting on the day of surgery, BCNI animals received penile injections with 1ug of SDF1 or saline QOD for 5 injections. Sham animals received saline penile injections only. 2 weeks after BCNI, intracorporeal pressure (ICP) response to cavernous nerve stimulation was assessed (n¼5/ group) and MPGs were collected and RNA was isolated (n¼5/ group). Stem cell activity in the MPG was assessed using a stem cell expression array expressed as mean fold-change AE SE normalized to sham.
RESULTS: SDF1 penile injections resulted in improved ICP preservation following BCNI compared to animals receiving saline injections. Sham animals had significantly greater (P<0.05, 1-way ANOVA with Tukey's post-hoc testing) than BCNI+saline at all voltages (2, 4, 6, 8v), whereas there was no significant difference between Sham and BCNI+SDF1 at any voltages. Additionally, BCNI+SDF1 had greater ICP at 2v and 4v compared to BCNI+saline (0.40AE0.09 vs. 0.11AE0.08, p<0.05 and 0.47AE0.11 vs. 0.12AE0.08, p<0.05, respectively). Stem cell-associated gene expression normalized to Shams was globally increased following BCNI and BCNI+SDF1 had a greater increase in expression compared to BCNI+saline (7.89AE0.67 fold vs. 1.87AE0.15 fold, p<0.0001). On subset analysis, stem cell pathways had significantly greater expression in BCNI+SDF1 compared to BCNI+saline including cytokines and growth factors (6.45AE0.63 vs. 1.86AE0.13, p<0.0001), Notch pathway (7.72AE0.96 vs. 1.95AE0.17, p<0.0001), Wnt pathway (7.01AE0.68 vs. 1.87AE0.12, p<0.0001), mesenchymal stem cell markers (6.33AE1.16 vs. 1.82AE0.40, p¼0.0015), and neural cell lineage markers (6.63AE0.51 vs. 1.85AE0.14, p¼0.0003).
CONCLUSIONS: SDF1 penile injections improve preservation of erectile function following BCNI and are associated with increased stem cell pathway activation in MPG. 
